US Bancorp DE Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

US Bancorp DE lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 59.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,884 shares of the biopharmaceutical company’s stock after selling 7,132 shares during the period. US Bancorp DE’s holdings in Amicus Therapeutics were worth $46,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at $55,000. R Squared Ltd purchased a new stake in shares of Amicus Therapeutics in the fourth quarter valued at $79,000. Virtu Financial LLC purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at $107,000. KBC Group NV grew its position in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,120 shares during the period. Finally, Stephens Inc. AR purchased a new stake in Amicus Therapeutics during the fourth quarter valued at about $101,000.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $8.98 on Wednesday. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The business has a 50-day moving average of $9.36 and a 200-day moving average of $10.11. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -49.89, a PEG ratio of 1.51 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on FOLD shares. Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.